1 |
Alemtuzumab
| 4件: Alemtuzumab Alemtuzumab; Campath; Lemtrada; MABCAMPATH | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 22件: 13 13, 15, 19, 20, 36, 43, 44, 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326 |
2 |
Avacopan
| 1件: AVACOPAN AVACOPAN | 1件: D11093
D11093
| 1件: C5AR1 C5AR1 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Staphylococcus aureus infection 💬 | 3件: 43 43, 44, 222 |
3 |
Azathioprine
| 3件: AZATHIOPRINE AZATHIOPRINE; Azatioprina; Imuran | 2件: D00238
D00238
,
D03033
| - | - | 21件: 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 |
4 |
Belimumab
| 2件: Belimumab Belimumab; BENLYSTA | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 12件: 11 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 |
5 |
Blisibimod
| 1件: Blisibimod Blisibimod | 1件: D10311
D10311
| - | - | 5件: 43 43, 44, 49, 63, 66 |
6 |
Cyclophosphamide
| 6件: Ciclofosfamida Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; Cyclophosphamide; Cyclophosphamidum; Cytoxan | 2件: D00287
D00287
,
D07760
| - | - | 45件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 |
7 |
Human immunoglobulin G
| 18件: Bivigam Bivigam; CUTAQUIG; CUVITRU; GAMMAGARD LIQUID; Gammaplex; GAMUNEX-C; Hizentra; HUMAN IMMUNOGLOBULIN G; HUMAN NORMAL IMMUNOGLOBULIN; HyQvia; Immune globulin; Immunoglobulin; IMMUNOGLOBULIN G; IVIg; KIOVIG; PANZYGA; Privigen; Vivaglobin | - | - | - | 11件: 11 11, 13, 14, 17, 35, 43, 45, 50, 51, 63, 65 |
8 |
Hydroxychloroquine
| 3件: Hydroxychloroquine Hydroxychloroquine; HYDROXYCHLOROQUINE SULFATE; PLAQUENIL | 1件: D08050
D08050
| - | - | 27件: 13 13, 34, 41, 43, 44, 45, 46, 48, 49, 53, 56, 63, 66, 84, 89, 90, 96, 97, 107, 218, 222, 224, 234, 254, 271, 298, 299 |
9 |
Infliximab
| 6件: Flixabi Flixabi; INFLECTRA; Infliximab; Remicade; REMSIMA; Zessly | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
10 |
Methotrexate
| 6件: Methotrexat Methotrexat; Methotrexate; METHOTREXATE SODIUM; METOJECT; METOTREXATO; Méthotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
11 |
Methylprednisolone
| 4件: Medrol Medrol; Methylprednisolon; Methylprednisolone; METHYLPREDNISOLONE ACETATE | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
12 |
Mycophenolate mofetil
| 3件: CellCept CellCept; Mycophenolate mofetil; Mycophenolate mofetil TEVA | 3件: D00752
D00752
,
D05094
,
D05095
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
13 |
Mycophenolic acid
| 5件: Acido Micofenolico Acido Micofenolico; MICOFENOLICO ACIDO; Mycophenolate; Mycophenolic Acid; Myfortic | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
14 |
Naltrexone
| 2件: Naltrexone Naltrexone; Naltrexone Hydrochloride | 2件: D02095
D02095
,
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 13件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
15 |
Prednisolone
| 3件: Prednisolona Prednisolona; Prednisolone; Prednisolonum | 8件: D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 43件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
16 |
Prednisone
| 3件: PREDNISONA PREDNISONA; Prednisone; RAYOS | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
17 |
Rituximab
| 6件: MABTHERA MABTHERA; Rituxan; RITUXIMAB; Rixathon; Ruxience; Truxima | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 49件: 6 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
18 |
Tocilizumab
| 3件: Actemra Actemra; RoActemra; Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
19 |
Vilobelimab
| 2件: IFX-1 IFX-1; Vilobelimab | 1件: D11838
D11838
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 43 43, 44, 269 |
20 |
Vitamin D
| 3件: Calciferol Calciferol; Cod liver oil; Vitamin D | - | - | - | 24件: 3 3, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299 |